All articles tagged with #immunotherapy
Scientists at the University of Southampton developed a four-armed antibody that enhances T cell activation by clustering immune receptors, significantly boosting the immune response against cancer in laboratory tests, offering a promising new approach for cancer immunotherapy.
Research suggests that COVID-19 mRNA vaccines may enhance the immune response in cancer patients, leading to longer survival when combined with immunotherapy, especially in lung and skin cancers. The findings, based on patient data and mouse studies, indicate a potential for developing universal cancer vaccines, though further clinical trials are needed.
Scientists discovered that blocking the TAK1 protein in cancer cells slows tumor growth and enhances immune system attack in mice, suggesting a potential target for improving cancer immunotherapy, especially for melanoma, though further research is needed for human application.
A mouse study demonstrates that an experimental mRNA treatment can rejuvenate immune cells, specifically T cells, potentially improving immune response in aging, but further research is needed to assess its applicability in humans.
A redesigned CD40 antibody drug, tested in a small clinical trial, has shown promising results by shrinking or eliminating tumors in some patients with metastatic cancers, with fewer side effects than previous versions, and appears to activate a systemic immune response.
Scientists have discovered that in colorectal cancer, two subtypes of regulatory T cells play opposing roles, with one subtype helping to restrain tumor growth and the other promoting it. This finding could lead to more targeted immunotherapies that selectively eliminate harmful Tregs, improving outcomes for patients.
Scientists at Northwestern Medicine have discovered that pancreatic tumors evade immune attack by using a sugar-based signal to hide, but they developed a monoclonal antibody that can restore immune responses in mice, offering hope for new treatments.
Scientists discovered that bacteria from the Japanese tree frog, Ewingella americana, can shrink and eliminate tumors in mice by attacking cancer cells and boosting the immune response, showing promise as a new cancer treatment, though further testing is needed for human application.
Former Senator Ben Sasse announced he has been diagnosed with stage-four pancreatic cancer, describing it as a death sentence but expressing a fight spirit and gratitude for his family, while highlighting the disease's late diagnosis and limited treatment options.
Scientists have discovered a gut bacterium from common tree frogs, Ewingella americana, that completely eradicates tumors in lab mice, outperforming current treatments and showing promise for future cancer therapies, with ongoing research to optimize its use.
Researchers discovered that a bacterium from the gut of the Japanese tree frog, Ewingella americana, can completely eradicate aggressive colon tumors in mice by selectively targeting tumor environments, killing cancer cells, and activating the immune system, outperforming standard treatments. While promising, further research is needed to determine safety and efficacy in humans.
Scientists have successfully engineered cancer-fighting T-cells inside patients' bodies for the first time, potentially making CAR T-cell therapy faster, cheaper, and more accessible for treating multiple myeloma, with promising early results and manageable side effects.
A study suggests that administering immune checkpoint inhibitors earlier in the day, before 3 p.m., significantly improves survival outcomes for patients with extensive-stage small cell lung cancer, highlighting the potential of chronotherapy to optimize cancer treatment by aligning it with the body's circadian rhythms.
The study presents a novel approach to counteract immune decline in aging by using mRNA delivered to the liver to produce key immune factors (DLL1, FLT3-L, IL-7), which rejuvenates T cell production, enhances vaccine responses, and improves tumor immunotherapy efficacy in aged mice, without adverse effects or autoimmunity.
Merck announced positive results from the Phase 3 KEYNOTE-B15 trial showing that combining KEYTRUDA (pembrolizumab) with Padcev (enfortumab vedotin) before and after surgery significantly improves survival and response rates in cisplatin-eligible muscle-invasive bladder cancer patients, with a safety profile consistent with known effects.